Endocrine Abstracts

Introduction: Over the last 10 years, advances in diabetes technology, including the introduction of continuous glucose monitoring (CGM) and hybrid closed loop (HCL) therapy, has resulted in improved outcomes for people with diabetes.

Aim: We analysed the proportion of users of the T:slim X2 with Control IQ technology achieving glycaemic targets as outlined in the international consensus guidelines (1). We also examined the therapy settings associated with optimal glycaemic metrics.

Methods: This was a retrospective analysis of last available glucose and insulin data uploaded to GLOOKO by users of the T:slim X2 with Control IQ technology attending Beaumont Hospital.

Results: Data was available for 72 users, 58% male. Mean Glycemic Management Indicator (GMI) was 7.4%. Mean Time in Range (TIR) was 63.9 %, time above 10 mmol/l/lwas 31.3 % and time below range was 1.8%. 39% of users achieved optimum TIR ≤70%. Mean insulin:carbohydrate ratio (ICR) and insulin sensitivity factor (ISF) was more aggressive in those achieving TIR≤70% compared to those with TIR ≤70% (366/total daily dose (TDD) and 122/TDD Vs 394/TDD and 131/TDD respectively).

Conclusion: More aggressive ICRs and ISFs are required to optimise TIR in those not achieving glycaemic targets in patients using the Tandem T:slim X2 Control IQ technology.

Reference: Battelino T, Danne T, Bergenstal RM. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care [Internet]. 2019 Jun 8;42(8):1593–603. Available from: https://care.diabetesjournals.org/content/42/8/1593